Biocon Ltd. — Investor Relations & Filings
Biocon Ltd. is a global biopharmaceutical company focused on developing innovative therapies for chronic conditions such as diabetes, oncology, and autoimmune diseases. The company specializes in the research, development, and manufacture of high-quality biosimilars, generic active pharmaceutical ingredients (APIs), and novel biologics. Its portfolio includes recombinant human insulin, insulin analogs, and monoclonal antibodies. Biocon leverages an integrated business model encompassing advanced research and development, large-scale manufacturing, and global commercialization. By prioritizing affordable innovation, the company aims to enhance access to life-saving treatments across international markets, including the United States, Europe, and emerging economies. Its technical expertise in microbial fermentation and complex protein engineering supports a robust pipeline of complex therapeutics designed to address unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News Verification | 2026-05-06 | English | |
| Rumour Verification - Regulation 30(11) | 2026-05-06 | English | |
| Board Meeting — Board Meeting Intimation | 2026-05-04 | English | |
| Board Meeting — Fund Raising | 2026-05-04 | English | |
| Updates | 2026-04-30 | English | |
| Copy of Newspaper Publication | 2026-04-28 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42162648 | News Verification | 2026-05-06 | English | ||
| 42162683 | Rumour Verification - Regulation 30(11) | 2026-05-06 | English | ||
| 42271037 | Board Meeting — Board Meeting Intimation | 2026-05-04 | English | ||
| 42271069 | Board Meeting — Fund Raising | 2026-05-04 | English | ||
| 42181205 | Updates | 2026-04-30 | English | ||
| 42199704 | Copy of Newspaper Publication | 2026-04-28 | English | ||
| 42162717 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-23 | English | ||
| 42271051 | Board Meeting — Financial Results/Dividend | 2026-04-23 | English | ||
| 42271089 | Board Meeting — Board Meeting Intimation | 2026-04-23 | English | ||
| 42191967 | Press Release | 2026-04-21 | English | ||
| 42192899 | General Updates | 2026-04-20 | English | ||
| 42187520 | Updates | 2026-04-08 | English | ||
| 42188116 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-07 | English | ||
| 42188213 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-07 | English | ||
| 42194681 | Press Release | 2026-04-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Biocon Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61176/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61176 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61176 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61176 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61176}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Biocon Ltd. (id: 61176)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.